Funding News Edition: January 08, 2020 See more articles in this edition
Name: Immune Tolerance Network
Application Due Date: March 3, 2020
Funds Available: NIAID intends to commit $27 million in fiscal year 2021 to fund one award
Recommended Application Budgets: Limited to $23 million per year in direct costs
Proposed Project Period: Must be seven years
Scientific/Research Contact: Leighton Thomas
You may have heard of the Immune Tolerance Network (ITN), which NIAID describes as “an international consortium of basic scientists and clinical investigators that performs clinical research to evaluate the safety and efficacy of methods that can induce the immune system to tolerate certain antigens for the treatment of immune-mediated disorders.”
For those interested in being part of ITN, we have good news: the Institute recently reissued the funding opportunity announcement (FOA) Immune Tolerance Network (UM1, Clinical Trial Required). Note the U-series activity code, which denotes a cooperative agreement. To learn more about this type of support mechanism, go to our Cooperative Agreements (U) webpage.
The scope of research that ITN will conduct includes:
- Designing and conducting clinical trials at all phases to evaluate the safety and efficacy of investigational products and approaches for inducing and maintaining immune tolerance in humans
- Designing and conducting mechanistic studies and developing tolerance assays as integral components of the clinical trials undertaken, as well as establishing biospecimen repositories
- Providing services for data management in collaboration with other resources provided by NIAID, bioinformatics analysis, and data sharing in a secure computing environment to support clinical trials and mechanistic studies
The Network may also support limited product development and nonclinical studies (e.g., toxicology, pharmacology, pharmacokinetics) essential for the subsequent evaluation of promising tolerance induction approaches in humans.
Read FOA for Research Priorities, Network Structure, and More
For examples of disease-specific research priorities within each of ITN’s three clinical areas—asthma and allergic diseases, autoimmune diseases, and transplantation—see the FOA, linked above.
Carefully read the funding opportunity as it contains all the information you need to know, including Network structure, resources that NIAID will provide, and how “immune tolerance” is defined for the purposes of this FOA. Also check the December 18, 2019 Guide notice that revises information about the FOA’s funding restrictions.
Get Better Acquainted With the Network
Go to the Immune Tolerance Network website for additional details, such as clinical trials, core facilities, and policies.